Halozyme (RV7) AI Stock Analysis

7 Followers

Halozyme

(XETRA:RV7)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Royalty Growth and DiversificationRapid royalty growth across six commercial products strengthens the recurring, high-margin foundation of Halozyme’s model. Contributions from both established brands and newer launches reduce reliance on a single product and support durable revenue expansion as partner adoption broadens.

Negative Factors

Patent Litigation RiskActive patent disputes create uncertainty around the timing and durability of future royalty streams tied to affected technology. Adverse rulings, delayed resolutions, or injunction outcomes could constrain commercialization, increase legal costs, and weaken the predictability of platform economics.

Halozyme (RV7) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 14.64B
Dividend Yield: ―
Average Volume (3M): 109
Price to Earnings (P/E): 36.5
Beta (1Y): 0.31
Revenue Growth: 31.83%
EPS Growth: -26.61%
Country: Germany
Employees: 423
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Halozyme Business Overview & Revenue Model

Company Description

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHAN...

Halozyme Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:60.27%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentPositive

The call communicated a strong operational and financial quarter with record revenue, robust royalty growth (+50% YoY), raised guidance, accelerated deal-making (five CLAs including expansion into ADCs and nucleic acids), and progress on Hypercon as a second platform. Key risks were emphasized around active patent litigation (Merck/Alteogen), increased operating investments (R&D/SG&A), conversion/uptake gaps for certain launches (e.g., OPDIVO conversion at 15% vs. target), and some execution/financing uncertainty around Hypercon manufacturing. On balance, the positive commercial momentum, durable high-margin royalty streams, substantial cash generation, and the pipeline/deal cadence significantly outweigh the legal and execution risks noted on the call.

Positive Updates

Record Quarterly Revenue and Strong YoY Growth

Total revenue of $481.0M in Q2 FY2026, up 48% year-over-year (from $325.7M), driven by strong royalty and collaboration revenue contributions.

Negative Updates

Active Litigation with Merck and Patent Uncertainty

Ongoing multi-jurisdictional litigation regarding Merck's use of MDASE technology (injunctions pursued in ~8 countries), PTAB PGR proceedings in the U.S. with appeals of four initial decisions and remaining decisions expected this fall — creates legal and timing uncertainty for future royalties.

Company Guidance

Halozyme raised its 2026 outlook to total revenue of $1.835–$1.91 billion (up ~31%–37% YoY), royalty revenues of $1.22–$1.245 billion (up ~41%–43% YoY), adjusted EBITDA of $1.225–$1.28 billion (including ~ $60 million of planned Hypercon/SurfBio investment) and non‑GAAP diluted EPS of $8.65–$9.0; the raise reflects a midpoint benefit of roughly $112.5 million. The upgrade follows a record Q2 (total revenue $481M, +48% YoY; royalty revenue $307.7M, +50% YoY; adjusted EBITDA $328.8M; non‑GAAP EPS $2.28), first‑half royalties of about $548M (implying H2 royalty run‑rates of roughly $336–$348M per quarter), $332.8M of share repurchases in Q2 (vs. a $400M FY target) and management’s expectation of continued sequential H2 royalty growth driven by recently launched ENHANZE products and established contributors (DARZALEX subcu, VYVGART Hytrulo, Phesgo).

Halozyme Risk Analysis

Halozyme disclosed 40 risk factors in its most recent earnings report. Halozyme reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Halozyme Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:RV7 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XERS	69Neutral	$1.85B	-106.59	-426.33%	―	36.33%	54.68%
ASND	68Neutral	$15.53B	18.38	190.44%	―	128.41%	―
LGND	68Neutral	$6.14B	121.05	5.22%	―	1.03%	8.35%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARWR	49Neutral	$8.41B	-26.57	-60.54%	―	16.85%	-80.39%
IONS	48Neutral	$6.85B	-11.68	-110.84%	―	-7.49%	-98.12%

* Healthcare Sector Average

Performance Comparison

DE:RV7 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:RV7	Halozyme Therapeutics	116.45	56.89	95.52%
ARWR	Arrowhead Pharmaceuticals, Inc.	59.53	19.22	47.68%
IONS	Ionis Pharmaceuticals Inc.	40.42	-34.26	-45.88%
LGND	Ligand Pharmaceuticals Inc	313.52	123.14	64.68%
ASND	Ascendis Pharma A/S	250.17	52.42	26.51%
XERS	Xeris Pharmaceuticals	10.35	0.48	4.86%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Halozyme AI Stock Analysis